Loading…

Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

Saved in:

Bibliographic Details
Published in:	Leukemia 2018-09, Vol.32 (9), p.2028-2031
Main Authors:	Pavlasova, Gabriela, Borsky, Marek, Svobodova, Veronika, Oppelt, Jan, Cerna, Katerina, Novotna, Jitka, Seda, Vaclav, Fojtova, Miloslava, Fajkus, Jiri, Brychtova, Yvona, Doubek, Michael, Pospisilova, Sarka, Mayer, Jiri, Mraz, Marek
Format:	Article
Language:	English
Subjects:	13/31 13/89 631/67/327 692/699/1541/1990/291/1621/1915 96 Antineoplastic agents B cells Brief Communication Cancer Research CD20 antigen Cellular signal transduction Chronic lymphocytic leukemia Critical Care Medicine Dosage and administration Drug therapy Genetic aspects Hematology Immunotherapy Intensive Internal Medicine Medicine Medicine & Public Health Monoclonal antibodies Oncology Proteomics Reorganization and restructuring Rituximab Targeted cancer therapy Technical institutes Universities and colleges
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!